

FORM PTO-1390 (REV 02-2005)		ATTORNEY DOCKET NUMBER 4126-4037
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.53) TBA 10/570734
INTERNATIONAL APPLICATION PCT/GB2004/003847	INTERNATIONAL FILING DATE 9 September 2004	PRIORITY DATE CLAIMED 9 September 2003
TITLE OF INVENTION NEW ANTITUMORAL COMPOUNDS		
APPLICANTS FOR DO/EO/US Ariadna Fernandez Donis, Ernest Giralt Lledó, Carolina Gracia Cantador, Pilar López Rodríguez, Sonia Varon Colomer, Carmen Cuevas Marchante, Ángel López Macia, Andrés Francesch Solloso, José-Carlos Jiménez Garcia, Miriam Royo Expósito, and Fernando Albericio Palomera		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. <input checked="" type="checkbox"/> The US has been elected. (Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). <input checked="" type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98, Forms PTO-1449 A and PTO-1449 B, with a copy of all cited references. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input type="checkbox"/> A preliminary amendment. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A power of attorney and/or change of address letter. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821-1.825. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). <input checked="" type="checkbox"/> Other items or Information: <p>Copies of: PCT Request; Form PCT/IB/311; published PCT application - Publication number WO 2005/023846 A1, published on 17 March 2005; International Search Report published on 17 March 2005.</p>		

U.S. APPLICATION NO. (USPTO FORM 1-2) 10/570734 TBA		INTERNATIONAL APPLICATION NO. PCT/GB2004/003847		ATTORNEY'S DOCKET NO. 4126-4037											
The following fees have been submitted 21. <input checked="" type="checkbox"/> Basic national fee\$300 22. <input checked="" type="checkbox"/> Examination fee If International preliminary examination report prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4).....\$100 All other situations.....\$200 23. <input checked="" type="checkbox"/> Search fee Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority\$100 International Search Report prepared and provided to the Office.....\$400 All other situations.....\$500				<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="text-align: left;">CALCULATIONS</th> <th style="text-align: left;">PTO USE ONLY</th> </tr> <tr> <td>\$300</td> <td></td> </tr> <tr> <td>\$200</td> <td></td> </tr> <tr> <td>\$400</td> <td></td> </tr> <tr> <td>\$900</td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY	\$300		\$200		\$400		\$900	
CALCULATIONS	PTO USE ONLY														
\$300															
\$200															
\$400															
\$900															
TOTAL OF 21, 22 and 23 =				\$900											
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.															
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE												
- 100 =	/50 =		x \$250.00	\$ --											
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).				\$											
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$											
Total claims	15 - 20 =	--	x \$50.00	\$ --											
Independent claims	2 - 3 =	--	x \$200.00	\$ --											
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$360											
TOTAL OF ABOVE CALCULATIONS =				\$1,260											
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$											
SUBTOTAL =				\$1,260											
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).				+ \$											
TOTAL NATIONAL FEE =				\$1,260											
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+ \$											
TOTAL FEES ENCLOSED =				\$1,260											
				Amount to be refunded:	\$										
				Amount to be charged:	\$										

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 13-4500 (Order No. 4126-4037) in the amount of \$1,260 to cover the above fees.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
 Deposit Account No. 13-4500 (Order No. 4126-4037). A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be
 included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and
 granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Enter Address Here
 Morgan & Finnegan, L.L.P.
 3 World Financial Center
 New York, New York 10281-2101
 Tel: (212) 415-8700
 Fax: (212) 415-8701

Signature 

Kenneth H. Sonnenfeld // Michael A. Willis
 Name

33285 // 53,913
 REGISTRATION NUMBER

IN THE UNITED STATES


 RECEIVING OFFICE (EO/US)
 DESIGNATED OFFICE (DO/US)
 ELECTED OFFICE (EO/US)

AP20 Rev'd PCT/PTO 06 MAR 2006

INTERNATIONAL APPLICATION NO. PCT/GB2004/003847	INTERNATIONAL FILING DATE 9 September 2004	PRIORITY DATE CLAIMED 9 September 2003
--	---	---

 TITLE OF INVENTION
 NEW ANTITUMORAL COMPOUNDS

APPLICANT(S)

Ariadna Fernandez Donis, Ernest Giralt Lledó, Carolina Gracia Cantador, Pilar López Rodríguez, Sonia Varon Colomer, Carmen Cuevas Marchante, Ángel López Macia, Andrés Francesch Solloso, José-Carlos Jiménez Garcia, Miriam Royo Expósito, and Fernando Albericio Palomera

 Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Attn: DO/EO/US

 VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
 (INTERNATIONAL APPLICATION (37 CFR 1.10(c)))


I declare that on **March 6, 2006** I deposited with the United States Postal Service in an envelope "Express Mail, Post Office to Addressee", bearing Label Number **EV 826876202 US**, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 and having an express mail certification which I executed, the following papers:

1. Transmittal Letter To The United States Designated/Elected Office;
2. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
3. Information Disclosure Statement under 37 CFR 1.97 and 1.98, Forms PTO-1449 A and PTO-1449 B, with copy of all cited references (5 references)
4. Copies of: PCT Request; Form PCT/IB/311; published PCT application - publication number WO 2005/023846 A1, published on 17 March 2005;
5. International Search Report published 17 March 2005; and
6. Return receipt postcard.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Michael Willis

(Typed or printed name of person making this verified statement)



(Signature of person making this verified statement)

March 6, 2006

Date

(Verified Certification of Express Mailing Date (International Application) [13-12])